Michael J. Doane, PhD

Director, Health Economics and Outcomes Research
Alkermes, Inc.

Poster(s):

• (274) Treatment patterns and healthcare resource utilization in patients with schizophrenia or bipolar I disorder in the 6 months following initiation of olanzapine/samidorphan versus other atypical antipsychotics
  Wednesday, October 29, 2025

• (351) The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data
  Wednesday, October 29, 2025